Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 61 publications
Novel Risk Scoring System for Patients with Metastatic Castration Resistant Prostate Cancer Treated with Lutetium-177-PSMA-617.
Journal: The oncologist
Published: June 01, 2026
Inflammatory biomarkers have a prognostic role in patients with metastatic castration-resistant prostate cancer treated with Lutetium-177-PSMA-617.
Journal: Cancer
Published: September 22, 2025
Age- and sex-based differences in the genomic profiles of patients with gastrointestinal and pancreatic neuroendocrine neoplasms.
Journal: The oncologist
Published: September 17, 2025
Clinical outcomes of lutetium-177-PSMA-617 in a racially diverse cohort of patients with metastatic castration-resistant prostate cancer.
Journal: The oncologist
Published: July 16, 2025
An increase in splenic volume after first-line immunotherapy is associated with worse PFS in patients with metastatic renal cell carcinoma.
Journal: The oncologist
Published: July 15, 2025
Baseline geriatric 8 (G8) screening tool predicts overall survival in metastatic urothelial carcinoma treated with immune checkpoint inhibitors.
Journal: The oncologist
Published: February 06, 2025
Phase II Trial of Opaganib Addition in Metastatic Castration-Resistant Prostate Cancer After Disease Progression on Abiraterone or Enzalutamide.
Journal: Cancer medicine
Published: January 27, 2025
Characteristics, Treatment, and Outcomes of Primary Urethral Cancer: A Multicenter Review Over Two Decades.
Journal: Clinical genitourinary cancer
Published: October 15, 2024
Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors.
Journal: Therapeutic advances in medical oncology
Published: August 28, 2024
Neoadjuvant cabozantinib restores CD8+ T cells in patients with locally advanced non-metastatic clear cell renal cell carcinoma: a phase 2 trial.
Journal: Research square
Published: August 16, 2024
Trop-2 and Ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes.
Journal: American journal of clinical pathology
Published: July 29, 2024
Last Updated: 09/26/2026